Human Papillomavirus and Cervical Cancer in Australasia and Oceania: Risk-factors, Epidemiology and Prevention

Vaccine

Volumn 26, Issue SUPPL. 12, 2008, Pages

  Garland, Suzanne M ^a,b   Brotherton, Julia M L ^c   Skinner, S Rachel ^c   Pitts, Marian ^d   Saville, Marion ^b   Mola, Glen ^e   Jones, Ronald W ^f  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d LA TROBE UNIVERSITY   (Australia)

^e UNIVERSITY OF PAPUA NEW GUINEA   (Papua New Guinea)

^f NATIONAL WOMEN S HOSPITAL   (New Zealand)

Author keywords

Asia Pacific; Australasia; HPV epidemiology; Oceania; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; AUSTRALIA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; FIJI; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION PREVENTION; NEW ZEALAND; PACIFIC ISLANDS; PAPUA NEW GUINEA; PRIORITY JOURNAL; RISK FACTOR; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION; VIRUS CARCINOGENESIS; VIRUS ETIOLOGY; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; AGED; AUSTRALIA; CHILD; FEMALE; FIJI; GOVERNMENT PROGRAMS; HEALTH POLICY; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NEW ZEALAND; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PAPUA NEW GUINEA; RISK FACTORS; SMOKING; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 50849133597     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.041     Document Type: Article

References (53)

1. Australian Institute of Health and Welfare. Cervical Screening in Australia 2004-2005. Cancer series No. 38. Canberra: Australian Institute of Health and Welfare, 2007.
2. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer Incidence in Five Continents. Vol. I to XI. IARC Scientific Publications No. 160. Lyon: IARC Press, 2007.
3. Condon J.R., Armstrong B.K., Barnes T.T., and Zhao Y.Y. Cancer incidence and survival for indigenous Australians in the Northern Territory. Aust N Z J Public Health 29 2 (2005) 123-128
4. Bramley D., Hebert P., Tuzzio L., and Chassin M. Disparities in indigenous health: a cross-country comparison between New Zealand and the United States. Am J Public Health 95 5 (2005) 844-850
5. The New Zealand Cervical Cancer Audit: Screening of Women with Cervical Cancer 2000-2002. Wellington: Ministry of Health, 2004.
6. Parkin D.M., Freddie Bray, Ferlay J., and Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
7. Castellsagué X, de Sanjose S, Aguado T, Louie KS, Bruni L, Muñoz J, et al. HPV and Cervical cancer in the World. 2007 Report. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Vaccine 2007; Vol. 25 Supp. 3. Availabe at: www.who.int/hpvcentre (last accessed: April 2008).
8. Rissel C.E., Richters J., Grulich A.E., de Visser R.O., and Smith A.M. Sex in Australia: selected characteristics of regular sexual relationships. Aust N Z J Public Health 27 2 (2003) 124-130
9. Rissel C.E., Richters J., Grulich A.E., deVisser R.O., and Smith A.M.A. Sex in Australia: First experiences of vaginal intercourse and oral sex among a representative sample of adults. Aust N Z J Public Health 27 2 (2003) 131-137
10. Smith A, Aguis, P. Dyson, S., Mitchell, A., Pitts, M. Secondary students and seuxal health: results of the 3rd national survey of Australian secondary school students, HIV/AIDS and sexual health. Monograph series No. 47. Melbourne: Australian Research Centre in Sex, Health and Society, Latrobe University, 2003.
11. Laws PJ, Grayson N, Sullivan EA. Australia's mothers and babies 2004. Perinatal statistics series No. 18. Sydney: AIHW National Perinatal Statistics Unit, 2006.
12. Australian Bureau of Statistics. National Health Survey: summary of results, 2004-05 Canberra: Australian Bureau of Statistics, 2006.
13. Muñoz N., Castellsagué X., de González A.B., and Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24 S3 (2006) S3/1-S3/10
14. Aust Government Dept Health Aging. National Notifiable Diseases Surveillance System: Notifications of a selected disease by age group, sex and year. Aust Government Dept Health Aging (2007)
15. Brotherton J.M.L. How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 26 (2008) 250-256
16. Clifford G.M., Smith J.S., Plummer M., Muñoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 Jan 13 (1) (2003) 63-73
17. Stevens M.P., Tabrizi S.N., Quinn M.A., and Garland S.M. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer 16 (2006) 1017-1024
18. Brestovac B., Harnett G.B., Smith D.W., Shellam G.R., and Frost F.A. Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women. J Med Virol 76 (2005) 106-110
19. Stevens M.P., Garland S.M., Rudland E., Tan J., Quinn M.A., and Tabrizi S.N. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol 45 (2007) 2130-2137
20. Garland SM, Brotherton J, Condon J, Tabrizi S, McIntyre P, Smith D, et al. Human Papillomavirus genotype prevalence in Australian women (Indigenous, non-Indigenous, urban, rural populations). In: 24th International Papillomavirus Conference and Clinical Workshop. Beijing, China, 2007.
21. Newall A.T., Brotherton J.M.L., Quinn H.E., Backhouse J., McIntyre P.B., Gilbert G.L., et al. Population seroprevalence to human papillomavirus types 6, 11, 16, and 18 in men, women and children in Australia. Clin Infect Dis 46 (2008) 1647-1655
22. Watson P., and On behalf of the Adolescent Health Research Group. A health profile of New Zealand youth who attend secondary school. NZ Med J 116 1171 (2003) U380-
23. Clark T., Robinson E., Crengle S., and Watson P. Contraceptive use by Maori youth in New Zealand: associated risk and protective factors. NZ Med J 119 1228 (2006) U1816
24. Baker M., Ortega-Benito J., Garret N., Bromhead C., Leslie K., MacDonald J., et al. Prevalence and risk factors for Chlamydia trachomatis infection in female New Zealand university students. NZ Med J 118 1220 (2005) U1607
25. Immunisation Handbook 2006. Wellington, New Zealand: Ministry of Health, 2006.
26. Meekin G., Sparrow M., Fenwicke R., and Tobias M. Prevalence of genital human papillomavirus infection in Wellington women. Genitourin Med 68 4 (1992) 228-232
27. Mgone C.S. Is uterine cervical cancer a potentially preventable sexually transmitted disease?. PNG Med J 41 2 (1998) 47-50
28. National Centre in HIV Epidemiology and Clinical Research. 2004 annual surveillance report: HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. Sydney: National Centre in HIV Epidemiology and Clinical Research, 2004.
29. Menzies R., and McIntyre P. Vaccine Preventable Diseases and Vaccination Policy for Indigenous Populations. Epidemiol Rev 28 (2006) 71-80
30. National Health and Medical Research Council. Screening to prevent cervical cancer: Guidelines for the management of asymptomatic women with screen detected abnormalities. Canberra: Australian Government National Health and Medical Research Council Publications, 2005. Available at: www.nhmrc.gov.au/publications (last accessed: April 2008).
31. The Report of the Cervical Cancer Inquiry Auckland, New Zealand: Government Printing Office, 1988.
32. Prasad K., and Fong J. The Effectiveness of Cervical Cancer Screening Programme At Colonial War Memorial Hospital. Fiji Med J 26 (2007) 9-12
33. Department of Health and Aging. New arrangements for vaccines: ATAGI and PBAC. 2006; Available at: http://www.medicinesaustralia.com.au/pages/images/Terry%20Nolan.pdf (last accessed: April 2008).
34. Henry D.A., Hill S.R., and Harris A. Drug Prices and Value for Money The Australian Pharmaceutical Benefits Scheme. JAMA 294 (2005) 2360-2362
35. Brotherton J., Wang H., Schaffer A., Quinn H., Menzies R., Hull B., et al. Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. Commun Dis Intell 31 Suppl. (2007) S1-S152
36. McIntyre P. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Commun Dis Intell 28 92-5 (2004)
37. Isaacs D., Lawrence G., Boyd I., Ronaldson K., and McEwen J. Reporting of adverse events following immunisation in Australia. J Paediatr Child Health 41 (2005) 163-166
38. Correll P., Hayen A., and Eyeson-Anan M. Hepatitis B immunisation in children aged 10-13 years in New South Wales. NSW Health Bulletin 14 1-2 (2003) 17-21
39. Skinner S.R., Nolan T., and Bowes G. Measles-mumps- rubella and hepatitis B vaccination uptake in adolescents: a survey in metropolitan Melbourne. Med J Aust 168 11 (1998) 546-549
40. Skinner S.R., Imberger A., Nolan T., Lester R., Glover S., and Bowes G. Randomised controlled trial of an educational strategy to increase school-based adolescent hepatitis B vaccination. Aust N Z J Public Health 24 3 (2000) 298-304
41. Skinner S.R., and Nolan T. Adolescent hepatitis B immunisation- should it be the law?. Aust N Z J Public Health 25 3 (2001) 230-233
42. Heron L, O'Connor B, Chant K, Jalaludin A. Cluster randomised trial of three hepatitis B vaccination programs targeting children in late primary school. In: Communicable Diseases Control Conference, March 31-April 1 2003:51.
43. Clements J. Gardasil and mass psychogenic illness. Aust N Z J Public Health 31 4 (2007) 387
44. Britt H, Miller GC, Knox S, Charles J, Pan Y, Henderson J, et al. General practice activity in Australia 2004-2005. General Practice Series No. 18. Canberra: Australian Institute of Health and Welfare, 2005.
45. Schwarz TF, Dubin G, HPV Vaccine Study Investigators for Adult Women. AS04-adjuvantedHPV16/18 L1 Vaccine for preventing cervical cancer is highly immunogenic and well tolerated in women over 25 years of age. American Society of Clinical Oncology 2006 May. ASCO Annual Meeting Proceedings part I, vol. 25, No. 18S (June 20 Supplement), 2007: 3007
46. Skinner S.R., Garland S.M., Stanley M.A., Pitts M., and Quinn M. HPV vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women over 26?. Med J Aust 188 4 (2008) 238-242
47. Pitts M.K., Dyson S.J., Rosenthal D.A., and Garland S.M. Knowledge and awareness of human papillomavirus (HPV): attitudes towards HPV vaccination among a representative sample of women in Victoria. Aust Sex Health 4 177-180 (2007)
48. McCaffery K., and Irwig L. Australian women's needs and preferences for information about human papillomavirus in cervical screening. J Med Screen 12 (2005) 134-141
49. Marshall H., Ryan P., Roberton D., and Baghurst P. A cross-sectional survey to assess community attitudes to introduction of Human Papillomavirus vaccine. Aust N Z J Public Health 31 3 (2007) 235-242
50. Hausdorf K., Newman B., Whiteman D., Aitken J., and Frazer I. HPV vaccination: what do Queensland parents think?. Aust N Z J Public Health 31 3 (2007) 288-289
51. McClelland A., and Liamputtong P. Knowledge and acceptance of human papillomavirus vaccination: perspectives of young Australians living in Melbourne, Australia. Sexual Health 3 (2006) 95-101
52. Rosenthal D.A., Dyson S., Pitts M., and Garland S.M. Challenges to accepting a Human PapillomaVirus (HPV) vaccine: A qualitative study of Australian women. Women Health 45 2 (2007) 59-73
53. Giles M., and Garland S.M. A study of women's knowledge regarding human papillomavirus infection, cervical cancer and human papillomavirus vaccines. Aust NZ J Obstet Gynaecol 46 (2006) 311-315